TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

83 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • COPD (chronic lung disease)

    A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

    Testing two doses of a medicine versus placebo for COPD symptoms

    📍 Research Site · Birmingham, AL · +39 more US sites · Get directions →

    This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.

    ✓ Study care freePhase 2Ages 40+Learn more →
  • COPD (chronic lung disease)

    Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

    Testing how a genetic change in alpha-1 antitrypsin affects immune and lung responses to a pneumonia

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.

    ✓ Study care freePhase 4Ages 19+Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +1 more US site · Get directions →

    This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →

    This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Surprise, AZ · +17 more US sites · Get directions →

    International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    Testing safety of a twice-yearly medicine for early relapsing MS

    📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

    The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    Testing whether combining a walking medication with physical therapy improves mobility in people

    📍 MGH Institute of Health Professions · Boston, MA · Get directions →

    The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

    ✓ Study care freePhase 4Ages 25–75Learn more →
  • Type 2 diabetesHigh blood pressure

    Polypill for Prevention of Cardiomyopathy

    Testing a pill combination to prevent heart muscle disease in people with type 2 diabetes and high

    📍 UT Southwestern Medical Center · Dallas, TX · Get directions →

    This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily.

    ✓ Study care freePhase 1Ages 18–100Learn more →
  • COPD (chronic lung disease)Asthma

    The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

    Testing whether positive airway pressure helps a lung medicine (NAC) reach mucus plugs in asthma or

    📍 UCSF Airway Clinical Research Center · San Francisco, CA · Get directions →

    The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.

    ✓ Study care freePhase 4Ages 18–85Learn more →
  • Multiple sclerosis (MS)

    A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    Testing a drug called BMS-986368 for muscle stiffness in multiple sclerosis

    📍 Alabama Neurology Associates · Birmingham, AL · +14 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • COPD (chronic lung disease)

    To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

    Testing two doses of a daily medicine versus placebo in people with COPD over 52 weeks

    📍 DM Clinical Research - Phoenix · Phoenix, AZ · +11 more US sites · Get directions →

    This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Multiple sclerosis (MS)

    A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

    Checking if two under-the-skin versions of ocrelizumab match in the body in people with multiple

    📍 Profound Research, LLC · Carlsbad, CA · +8 more US sites · Get directions →

    The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

    Testing whether daily soy milk affects liver disease in children with fatty liver

    📍 Cincinnati Children's Hospital Medical Center · Cincinnati, OH · Get directions →

    A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities.

    ✓ Study care freePhase 2Ages 5–12Learn more →
  • Multiple sclerosis (MS)

    Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

    Testing whether corticosteroids change inflammation in acute MS lesions

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways.

    ✓ Study care freePhase 2Ages 18–120Learn more →
  • Fatty liver disease (NASH/MASH)

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.

    ✓ Study care freePhase 2Ages 18–100Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health - Chandler · Chandler, AZ · +30 more US sites · Get directions →

    Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse

    ✓ Study care freePhase 2Ages 30+Learn more →
  • Multiple sclerosis (MS)

    Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

    Testing solriamfetol to treat tiredness from multiple sclerosis

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness.

    ✓ Study care freePhase 2Ages 18–60Learn more →
  • Fatty liver disease (NASH/MASH)

    Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

    Testing how SGLT2 inhibitors work for fatty liver disease in obese teens

    💵 May compensate

    📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

    ✓ Study care freePhase 2Ages 16–20Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Fibrosis Lessens After Metabolic Surgery

    Testing whether metabolic surgery can reduce liver scarring in obesity

    💵 May compensate

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Home Based Infusions for Ocrelizumab

    Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis

    📍 Amerita · Centennial, CO · Get directions →

    The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

    Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the

    📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →

    The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.

    ✓ Study care freePhase 2Ages 35–89Learn more →
  • Multiple sclerosis (MS)

    Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

    Testing whether TRX319 is safe for people with progressive multiple sclerosis

    📍 University of Kansas Medical Center · Kansas City, KS · +1 more US site · Get directions →

    The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS?

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Testing a medicine to reduce brain and eye tissue loss in people with multiple sclerosis

    📍 Johns Hopkins University · Baltimore, MD · +1 more US site · Get directions →

    The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

    ✓ Study care freePhase 2Ages 18–60Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    Testing efimosfermin in people with MASH-related compensated cirrhosis

    💵 May compensate

    📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

    Testing whether special MRI using hyperpolarized carbon can predict how relapsing-remitting MS

    📍 Byers Hall · San Francisco, CA · Get directions →

    The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy. Study procedures will include magnetic resonance imaging (MRI) assessments with a hyperpolarized pyruvate sequence, clinical assessment as well as blood markers of disease progression.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • COPD (chronic lung disease)

    Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

    Testing an add-on treatment for adults having a COPD flare with type 2 inflammation

    📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +21 more US sites · Get directions →

    This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • High blood pressureDementia / Alzheimer's

    Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

    Testing whether tightly lowering high blood pressure slows brain changes tied to Alzheimer’s

    📍 University of Texas Southwestern Medical Center · Dallas, TX · Get directions →

    The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.

    ✓ Study care freePhase 2Ages 60–85Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

    Testing a medicine at two doses for safety and effects on fats in people with high triglycerides and

    💵 May compensate

    📍 OrsoBio Research Site · Guadalajara, Jalisco · Get directions →

    This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • COPD (chronic lung disease)

    A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

    Testing different doses of two inhaled medicines for COPD symptoms

    📍 SEC Clinical Research, LLC · Dothan, AL · +39 more US sites · Get directions →

    This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Multiple sclerosis (MS)

    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

    Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • COPD (chronic lung disease)

    Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

    Comparing inhaled triple versus double medicines for COPD lung airways after wood smoke exposure

    💵 May compensate

    📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →

    This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.

    ✓ Study care freePhase 4Ages 35–85WomenLearn more →
  • COPD (chronic lung disease)

    Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

    Comparing nebulizer and inhaler treatments for COPD symptoms

    📍 The University of Tennessee Graduate School of Medicine · Knoxville, TN · Get directions →

    The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Multiple sclerosis (MS)

    Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

    Testing metformin alone or with other treatment in older people with multiple sclerosis

    📍 UBMD Neurolgy · Buffalo, NY · Get directions →

    The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy.

    ✓ Study care freePhase 2Ages 55–75Learn more →
  • Obesity / overweightHigh blood pressure

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Testing treatments to lower high pressure in liver veins in people with advanced liver disease and

    💵 May compensate

    📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • COPD (chronic lung disease)

    A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

    Testing how a study medicine affects safety and symptoms in people with COPD

    📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.

    ✓ Study care freePhase 2Ages 35–80Learn more →
  • Obesity / overweightHigh blood pressureCOPD (chronic lung disease)

    Feasibility of Semaglutide in Advanced Lung Disease

    Testing whether semaglutide can be given safely to people with advanced lung disease

    📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →

    The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • COPD (chronic lung disease)

    A Study to Evaluate Solrikitug in Participants With COPD (ZION)

    Testing solrikitug in people with COPD to check safety and effects

    📍 University of Alabama at Birmingham Hospital · Birmingham, AL · +39 more US sites · Get directions →

    A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).

    ✓ Study care freePhase 2Ages 40–75Learn more →
  • Multiple sclerosis (MS)

    Glucose Consumption in MS Using [F-18]FDG-PET

    Testing how [F-18]FDG PET shows glucose use in people with MS and controls

    📍 Brigham & Women's Hospital · Boston, MA · Get directions →

    Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting MS (RRMS), as well as healthy controls.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Multiple sclerosis (MS)

    Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

    Testing whether silodosin helps lower urinary tract symptoms in women with multiple sclerosis

    📍 Atlantic Health · Morristown, NJ · Get directions →

    The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Multiple sclerosis (MS)

    Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

    Testing whether clemastine fumarate changes MRI signs of nerve repair in people with multiple

    📍 Sandler Neurosciences Building, Neurological Clinical Research Unit · San Francisco, CA · Get directions →

    The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments. No reparative therapies exist for the treatment of multiple sclerosis.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • Multiple sclerosis (MS)

    Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

    Testing a nasal treatment in people with non-active secondary progressive multiple sclerosis

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible to be enrolled in TILS-022. TILS-022 is a 6-month open-label extension study with an opportunity for dose to be escalated based on the subject's clinical status.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis

    Testing cognitive behavioral therapy to treat insomnia symptoms in people with multiple sclerosis

    📍 University of Kansas Medical Center · Kansas City, KS · Get directions →

    The incidence of insomnia is estimated to be as high as 90% in individuals with MS due to insomnia being underdiagnosed. Sleep disturbances in people with MS have been associated with reduced cognitive performance, physical function, psychological well-being, quality of life, and occupational function, as well as increased prevalence of fatigue, pain, depression, and anxiety.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection

    Testing telehealth versus web-based CBT for sleep and fatigue in people with multiple sclerosis

    📍 University of Kansas Medical Center- Sleep, Health and Wellness Laboratory · Kansas City, KS · Get directions →

    The objective of this RCT is to assess the efficacy of one-on-one telehealth CBT-I (tCBT-I) compared to web-based CBT-I (wCBT-I) and treatment as usual (TAU) to improve sleep outcomes (Aim 1), fatigue and quality of life (Aim 2), and promote neuroprotection (Exploratory Aim 3), and to explore the characteristics of participants that predict improvement in sleep outcomes (Exploratory Aim 4). Reassessment of outcomes will be completed after the 6-week intervention and 6 months following completion of interventions.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

    Testing eye-tracking measures to track disease changes in relapsing-remitting multiple sclerosis

    📍 Novartis Investigative Site · Calgary, Alberta · Get directions →

    The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

    ✓ Study care freePhase 4Ages 18–99Learn more →
  • Multiple sclerosis (MS)

    A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

    Testing how fenebrutinib affects the body and safety in children with relapsing multiple sclerosis

    📍 INECO Neurociencias Orono · Rosario, Santa Fe Province · Get directions →

    This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and \< 18 years. This study consists of a Dose Exploration Period and an Optional Extension Period.

    ✓ Study care freePhase 2Ages 10–17Learn more →
  • COPD (chronic lung disease)

    A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

    Testing the right dose of a long-acting medicine for moderate to severe COPD

    📍 WB Contracted Clinical Research Site · Miami Lakes, FL · +3 more US sites · Get directions →

    This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Milk Thistle Clinical Trial in Pediatric NAFLD

    Testing milk thistle for children with fatty liver disease

    💵 May compensate

    📍 University Hospitals Cleveland Medical Center · Cleveland, OH · Get directions →

    Pediatric Fatty Liver disease is a growing problem in the United States and is expected to be the leading cause of Liver Transplantation in Adults in 20 years. Following lifestyle changes such as diet restrictions and exercise may be difficult to consistently maintain.

    ✓ Study care freePhase 2Ages 9–22Learn more →
  • Fatty liver disease (NASH/MASH)

    Digoxin In NASH (CODIN)

    Testing digoxin for people with metabolic fatty liver inflammation

    📍 Yale New Haven Health · New Haven, CT · +1 more US site · Get directions →

    Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metabolic associated steatohepatitis (MASH), involves lifestyle interventions to promote weight loss and to treat comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • High blood pressureKidney disease

    Equol and Vascular Function in Women With Chronic Kidney Disease

    Testing whether equol affects blood vessel function in women with chronic kidney disease

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.

    ✓ Study care freePhase 2Ages 50+WomenLearn more →
  • Multiple sclerosis (MS)

    A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

    Testing the safety of an mRNA treatment to help prevent multiple sclerosis relapses

    📍 Boston Clinical Trials Inc - Internal Medicine · Boston, MA · +7 more US sites · Get directions →

    The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.

    ✓ Study care freePhase 2Ages 18–55Learn more →
  • Multiple sclerosis (MS)

    A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

    Testing whether starting metformin at different times is feasible in youth with multiple sclerosis

    📍 The Hospital for Sick Children · Toronto, Ontario · Get directions →

    A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.

    ✓ Study care freePhase 1Ages 10–25Learn more →
  • COPD (chronic lung disease)

    The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

    Studying how sleep apnea together with COPD affects heart health

    📍 UCSD Sleep Research · La Jolla, CA · Get directions →

    Major progress has been made in the area of cardiovascular disease, but we believe that further progress will involve mechanistically addressing underlying respiratory causes including chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). The most common cause of death in COPD is cardiovascular, although mechanisms are unknown.

    ✓ Study care freePhase 2Ages 40–79Learn more →
  • Multiple sclerosis (MS)

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

    Testing stopping ocrelizumab in people with relapsing multiple sclerosis

    📍 Yale School of Medicine · New Haven, CT · +12 more US sites · Get directions →

    This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Dementia / Alzheimer'sParkinson's diseaseMultiple sclerosis (MS)

    Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

    Testing safety of a PET imaging tracer in people with ALS, AD, MS, PD

    📍 UCSF · San Francisco, CA · +2 more US sites · Get directions →

    This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

    Testing resmetirom in people with MASH-related liver scarring after liver transplant

    💵 May compensate

    📍 University of California San Diego · La Jolla, CA · +15 more US sites · Get directions →

    A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Dementia / Alzheimer'sMultiple sclerosis (MS)

    PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

    Testing PET brain scans to measure immune cell activity in dementia

    📍 Brigham MS Center, 60 Fenwood Road · Boston, MA · Get directions →

    The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Multiple sclerosis (MS)

    Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

    Testing how single or combined medicines affect MS biomarkers

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers.

    ✓ Study care freePhase 1Ages 18–120Learn more →
  • Showing the first 60 of 83. Add filters or a location to narrow down.